ReleaseWire Connect

Global Market Research Report on Noninvasive Cancer Diagnostics and Technologies System Market 2016 is a professional and in-depth complete study on the current state of the Noninvasive Cancer Diagnostics and Technologies System worldwide.

Non-invasive diagnostics is a process of identifying the disease conditions with minimal incision to the body during diagnosis. Non-invasive diagnostic market is segment of diagnostic market, which was valued at approximately $46 billion in 2011. The non-invasive diagnostic market is mainly driven by increasing rate of prevalence of chronic disease such as CVD, Neurological disease. More than 64.4 million people are suffering from various type of CVD in the U.S, out of which nearly 2,600 people die in a day. The growth of non-invasive diagnostics market has been hindered by availability of non-invasive diagnostic services. Developing countries are not getting non-invasive diagnostic services due to lack of awareness.

Pediatric healthcare is dealing with the treatment of child related diseases, their development and care. Children often suffer from respiratory, gastrointestinal and other chronic disease because of lower immunity. The global market for Pediatric healthcare is accounted to approximately $83 billion in 2013 and expected to grow at 7.8% CAGR in future. Increase in demand for chronic disease treatment, Diarrhea and injury related disease is more common in children; however, these diseases vary from short term to long-term treatments that consume a lot time and exert financial pressures on the parents. Changes in child care trend increases the prevalence rate of pediatric diseases. This report provides detail information about current scenario of pediatric treatment and expected growth in it.

Diabetes care market comprises of technologies, devices and therapeutics markets in relation to diabetes. As estimated by The World Diabetes Foundation, there would be 438 million people suffering from diabetes by 2030. Approximately 11.6% of the global healthcare expenditure is shared by diabetes care. In 2010, global expenditure on diabetes was $376 billion. Global diabetes management product market was valued $41 billion in 2012. Sedentary lifestyle and obesity are primary factors driving the diabetes care market. There has been a considerable rise in the number of diabetes cases globally over the last few years. Improper diet and sedentary lifestyle are the main risk-elevating factors. Currently, about 528.7 million people are suffering from obesity, which is a primary reason for development of diabetes in people.

The Histone deactylase inhibitor (HDAC) is a molecule that consists of different compounds that form a group of anticancer agents. The parent epigenetic market of HDAC is expected to grow at a CAGR of around 30% worldwide from 2013 to 2020. The factors driving this market are increase in cancer incidences, ongoing research and development for the treatment of cancer, other diseases, and the need to improve the effectiveness of new therapies. The major limitation of this market is reimbursement and uncertainty issues. The opportunities for this market are increase in collaborations and huge investments in manufacturing which will ensure significant growth.

Protein therapeutics is artificially synthesized protein on large scale through genetically modified host cells that is used in treatment of chronic diseases such as cancer, diabetes and CVD. According to IMS Health Market Prognosis, the total market size of pharmaceutical industry was approximately $962.1 billion in 2012. This shows growth opportunities for protein therapeutics market. High efficiency of protein therapeutics with fewer side effects is driving the protein therapeutics market. For example, Approximately 17.7 adults consumed oral medication (Pills or insulin) for diabetes in 2011. Protein therapeutics market growth is hindered by adverse side effects in chronic diseases and cost of production.